German pharmaceutical giant Merck is set to invest $70 million to expand its EMD Serono research and development (R&D) facility in Billerica, Massachusetts. This major investment will support the company’s efforts in advancing drug discoveries, specifically in oncology, immuno-oncology, and immunology. The expansion, which includes the construction of a new 145,000 square-foot building, will help Merck strengthen its biopharma pipeline and further enhance its presence in North America.

Key Features of the Expansion

The new building at the EMD Serono facility will include state-of-the-art wet labs, office spaces, and a cafeteria, creating a collaborative environment for researchers. Upon completion, which is targeted for 2021, it will house approximately 400 R&D employees, both new hires and existing staff. This expansion follows a long-term investment strategy by Merck, which has already poured over $150 million into Massachusetts-based biopharma infrastructure since 2011.

Strengthening Merck’s Global R&D Footprint

Luciano Rossetti, Head of Global Research & Development at Merck, highlighted the importance of the Billerica R&D site, noting that the team has been critical in advancing various pipeline compounds. Rossetti emphasized the company’s ongoing commitment to innovation, which spans both the U.S. and Germany—where Merck’s global R&D headquarters are located. With this expansion, Merck aims to deliver transformative solutions for patients globally.

Contributions to Massachusetts’ Life Sciences Sector

The investment marks another milestone in Merck’s contribution to the Massachusetts life sciences sector, which has long been recognized for its global leadership in biotech and pharmaceutical innovation. Travis McCready, President and CEO of the Massachusetts Life Sciences Center, praised the company’s continued investment in the state, noting that it has not only attracted top-tier talent but has also played a significant role in improving public health.

Implications for the Local Economy

This expansion is expected to further strengthen Merck’s role as a key player in the U.S. life sciences ecosystem, contributing to the local economy by creating new jobs and enhancing the company’s ability to drive cutting-edge research. The partnership with Billerica further demonstrates Merck’s ongoing investment in the future of biopharmaceutical innovation in the region.

  Billerica, biopharma, EMD Serono, immunology, Luciano Rossetti, Massachusetts, Merck, Oncology, R&D, Travis McCready